Get the Stockscreener App
5.61
3.12%
0.17
Cogent Biosciences Inc stock is traded at $5.61, with a volume of 3.40M.
It is up +3.12% in the last 24 hours and down -4.43% over the past month.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.
See More
Previous Close:
$5.44
Open:
$5.77
24h Volume:
3.40M
Relative Volume:
2.49
Market Cap:
$638.75M
Revenue:
-
Net Income/Loss:
$-242.30M
P/E Ratio:
-2.2621
EPS:
-2.48
Net Cash Flow:
$-192.10M
1W Performance:
+16.39%
1M Performance:
-4.43%
6M Performance:
-40.76%
1Y Performance:
-29.96%
1-Day Range:
$5.10
$6.10
1-Week Range:
$4.795
$6.10
52-Week Range:
$3.72
$12.61
Cogent Biosciences Inc Stock (COGT) Company Profile
Name
Cogent Biosciences Inc
Sector
Industry
Phone
617-945-5576
Address
275 WYMAN STREET, WALTHAM
Compare COGT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
COGT
Cogent Biosciences Inc
|
5.61 | 555.62M | 0 | -242.30M | -192.10M | -2.48 |
|
ONC
Beone Medicines Ltd Adr
|
245.93 | 25.76B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.43 | 114.53B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.415 | 40.54M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
84.10 | 6.44B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.81 | 65.13B | 14.09B | 4.50B | 2.96B | 39.28 |
Cogent Biosciences Inc Stock (COGT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Dec-11-24 | Downgrade | Needham | Buy → Hold |
| Feb-26-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Feb-08-24 | Initiated | Citigroup | Buy |
| Dec-11-23 | Downgrade | Wedbush | Outperform → Neutral |
| Dec-08-23 | Initiated | JP Morgan | Overweight |
| Apr-28-23 | Initiated | Robert W. Baird | Outperform |
| Mar-27-23 | Resumed | H.C. Wainwright | Buy |
| Dec-14-22 | Initiated | Needham | Buy |
| Jun-28-22 | Initiated | Guggenheim | Buy |
| Oct-11-21 | Initiated | H.C. Wainwright | Buy |
| Jun-09-21 | Resumed | Jefferies | Buy |
| Dec-23-20 | Initiated | Piper Sandler | Overweight |
| Oct-14-20 | Initiated | Ladenburg Thalmann | Buy |
View All
Cogent Biosciences Inc Stock (COGT) Latest News
ProShare Advisors LLC Increases Stock Holdings in Cogent Biosciences, Inc. (NASDAQ:COGT) - Defense World
Cogent Biosciences (NASDAQ:COGT) Trading Down 5.7% – Time to Sell? - Defense World
Cogent Biosciences (NASDAQ:COGT) Price Target Raised to $25.00 at JPMorgan Chase & Co. - Defense World
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Grows Stock Holdings in Cogent Biosciences, Inc. (NASDAQ:COGT) - Defense World
Cogent Biosciences (NASDAQ:COGT) Shares Up 11.6% Following Analyst Upgrade - Defense World
COGT: JP Morgan Raises Price Target for Cogent Biosciences | COG - GuruFocus
Cogent Biosciences Announces Participation in the Jefferies Glob - GuruFocus
Cogent Biosciences Announces Participation in the Jefferies Global Healthcare Conference - GlobeNewswire
Cogent Biosciences Announces Participation in the Jefferies Global Healthcare Conference | COGT Stock News - GuruFocus
JPMorgan Ups Price Target for Cogent Biosciences (COGT) to $25 | - GuruFocus
Cogent Biosciences Reveals Latest Precision Therapy Progress Plus New Employee Stock Options - Stock Titan
Deutsche Bank AG Reduces Position in Cogent Biosciences, Inc. (NASDAQ:COGT) - Defense World
Jane Street Group LLC Decreases Stake in Cogent Biosciences, Inc. (NASDAQ:COGT) - Defense World
This Cogent Biosciences Insider Increased Their Holding By 2,085% Last Year - simplywall.st
When (COGT) Moves Investors should Listen - news.stocktradersdaily.com
BNP Paribas Financial Markets Buys Shares of 66,784 Cogent Biosciences, Inc. (NASDAQ:COGT) - Defense World
Janus Henderson Group PLC Has $227,000 Position in Cogent Biosciences, Inc. (NASDAQ:COGT) - Defense World
Q2 EPS Estimate for Cogent Biosciences Raised by Analyst - Defense World
Brokerages Set Cogent Biosciences, Inc. (NASDAQ:COGT) PT at $14.29 - Defense World
HC Wainwright Has Lowered Expectations for Cogent Biosciences (NASDAQ:COGT) Stock Price - Defense World
Cogent Biosciences (COGT) Maintains 'Buy' Rating with Adjusted P - GuruFocus
Cogent Biosciences (COGT) Maintains 'Buy' Rating with Adjusted Price Target | COGT Stock News - GuruFocus
Cogent Biosciences (COGT) Price Target Reduced by H.C. Wainwrigh - GuruFocus
Northern Trust Corp Grows Position in Cogent Biosciences, Inc. (NASDAQ:COGT) - Defense World
Where are the Opportunities in (COGT) - news.stocktradersdaily.com
Price T Rowe Associates Inc. MD Has $388,000 Stock Holdings in Cogent Biosciences, Inc. (NASDAQ:COGT) - Defense World
Wall Street Analysts Believe Cogent Biosciences (COGT) Could Rally 224.37%: Here's is How to Trade - MSN
Voya Investment Management LLC Sells 2,333 Shares of Cogent Biosciences, Inc. (NASDAQ:COGT) - Defense World
Why Cogent Biosciences (COGT) Is One of the Best Low Priced Biotech Stocks to Buy Now - MSN
Hsbc Holdings PLC Purchases Shares of 10,674 Cogent Biosciences, Inc. (NASDAQ:COGT) - Defense World
10 Best Low-Priced Biotech Stocks to Buy Now - Insider Monkey
Q2 EPS Estimate for Cogent Biosciences Lifted by Analyst - Defense World
Dimensional Fund Advisors LP Lowers Stock Holdings in Cogent Biosciences, Inc. (NASDAQ:COGT) - Defense World
Research Analysts Offer Predictions for COGT FY2028 Earnings - Defense World
Robert W. Baird Cuts Cogent Biosciences (NASDAQ:COGT) Price Target to $7.00 - Defense World
Cogent Biosciences (NASDAQ:COGT) Releases Earnings Results, Beats Estimates By $0.04 EPS - MarketBeat
Cogent Biosciences (COGT) Maintains Neutral Rating Amid PT Adjus - GuruFocus
Stock Surge: Cogent Biosciences Inc (COGT) Closes at 4.70, Marking a -15.62 Increase/Decrease - DWinneX
Cogent Biosciences (COGT) Maintains Neutral Rating Amid PT Adjustment | COGT Stock News - GuruFocus
Cogent Biosciences (COGT) Price Target Reduced by Baird | COGT Stock News - GuruFocus
Cogent Biosciences Advances with Promising Clinical Trials - TipRanks
MetLife Investment Management LLC Has $443,000 Stock Holdings in Cogent Biosciences, Inc. (NASDAQ:COGT) - Defense World
Cogent Biosciences Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference - Barchart.com
Wedbush Trims Price Target on Cogent Biosciences to $10 From $11, Maintains Neutral Rating - marketscreener.com
Cogent Biosciences Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Cogent Biosciences Inc (COGT) Q1 2025 Earnings: EPS Misses at -0 - GuruFocus
Cogent Biosciences (COGT) Plans Strategic Data Announcements in 2025 | COGT Stock News - GuruFocus
Cogent Biosciences Reports First Quarter 2025 Financial Results - GlobeNewswire
Form 424B5 Cogent Biosciences, Inc. - StreetInsider
BRIEF-Cogent Biosciences Q1 Income From Operations USD -74.933 Million - TradingView
Cogent Biosciences Gears Up for 3 Major Clinical Trial Readouts in 2025, Maintains Strong $245M Cash Reserve - Stock Titan
Cogent Biosciences Inc Stock (COGT) Financials Data
Revenue
Net Income
Cash Flow
EPS
6.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):